Pharma-Bio Serv (PBSV) Cash & Current Investments (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Cash & Current Investments for 17 consecutive years, with $8.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments fell 18.58% year-over-year to $8.5 million; the trailing twelve-month figure through Apr 2026 stood at $8.5 million (down 18.58% YoY), and the FY2025 full-year result was $10.9 million, down 14.84% from the prior year.
• Cash & Current Investments declined to $8.5 million in Q2 2026 per PBSV's latest filing, from $10.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $15.9 million in Q1 2024 and bottomed at $8.5 million in Q2 2026.
• Historically, Cash & Current Investments has averaged $13.0 million across 5 years, with a median of $13.3 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments advanced 3.56% in 2023, then fell 22.75% in 2025.
• Over 5 years, Cash & Current Investments stood at $14.5 million in 2022, then increased by 3.56% to $15.0 million in 2023, then slipped by 14.9% to $12.7 million in 2024, then dropped by 14.84% to $10.9 million in 2025, then declined by 21.95% to $8.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $8.5 million, $10.6 million, and $10.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.